| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.094 | 0.01 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | 0.093 | 0.01 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.097 | 0.01 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.01 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.16 | 0.01 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | -0.096 | 0.01 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | -0.2 | 0.01 |
| mRNA | CBB-1007 | CTRPv2 | pan-cancer | AAC | -0.15 | 0.01 |
| mRNA | nakiterpiosin | CTRPv2 | pan-cancer | AAC | 0.09 | 0.01 |
| mRNA | Midostaurin | GDSC1000 | pan-cancer | AAC | -0.094 | 0.01 |